Eli Lilly (LLY) partners with British government for a first-of-its-kind real-world study on economic effects of its weight ...

Earlier this year, J.P. Morgan released a report outlining the potential for GLP-1 treatments in other markets. Specifically, ...

In a bid to combat obesity and unemployment, the UK govt is collaborating with Eli Lilly, which will invest £279 mn in a ...

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.

The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...

Pharmacists can continue making compounded versions of generic tirzepatide, the active ingredient in popular medications ...

All of this means Lilly investors shouldn't panic. Even in the "worst case," Lilly's weight loss drugs have driven major revenue growth, and this is likely to continue -- whether compounders halt ...

A weight-loss drug more effective than Ozempic and Wegovy has recently been approved. Here’s how it works and how it compares ...

Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the U.S. Food and ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Compounding pharmacies can make tirzepatide againIn a reversal, the Food and Drug Administration ...

The logic suggested by the Lilly trial is the opposite, however. It proposes that being overweight is a primary cause of ...